在 zVADfmk 和 zLLYfmk 的存在下扩增脐带血 CD34 细胞可提高其体外功能和在 NOD/SCID 小鼠体内的植入。

Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in vivo engraftment in NOD/SCID mouse.

出版信息

PLoS One. 2010 Aug 17;5(8):e12221. doi: 10.1371/journal.pone.0012221.

Abstract

BACKGROUND

Cord blood (CB) is a promising source for hematopoietic stem cell transplantations. The limitation of cell dose associated with this source has prompted the ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs). However, the expansion procedure is known to exhaust the stem cell pool causing cellular defects that promote apoptosis and disrupt homing to the bone marrow. The role of apoptotic machinery in the regulation of stem cell compartment has been speculated in mouse hematopoietic and embryonic systems. We have consistently observed an increase in apoptosis in the cord blood derived CD34(+) cells cultured with cytokines compared to their freshly isolated counterpart. The present study was undertaken to assess whether pharmacological inhibition of apoptosis could improve the outcome of expansion.

METHODOLOGY/PRINCIPAL FINDINGS: CB CD34(+) cells were expanded with cytokines in the presence or absence of cell permeable inhibitors of caspases and calpains; zVADfmk and zLLYfmk respectively. A novel role of apoptotic protease inhibitors was observed in increasing the CD34(+) cell content of the graft during ex vivo expansion. This was further reflected in improved in vitro functional aspects of the HSPCs; a higher clonogenicity and long term culture initiating potential. These cells sustained superior long term engraftment and an efficient regeneration of major lympho-myeloid lineages in the bone marrow of NOD/SCID mouse compared to the cells expanded with growth factors alone.

CONCLUSION/SIGNIFICANCE: Our data show that, use of either zVADfmk or zLLYfmk in the culture medium improves expansion of CD34(+) cells. The strategy protects stem cell pool and committed progenitors, and improves their in vitro functionality and in vivo engraftment. This observation may complement the existing protocols used in the manipulation of hematopoietic cells for therapeutic purposes. These findings may have an impact in the CB transplant procedures involving a combined infusion of unmanipulated and expanded grafts.

摘要

背景

脐带血(CB)是造血干细胞移植的有前途的来源。与该来源相关的细胞剂量限制促使造血干细胞和祖细胞(HSPC)的体外扩增。然而,已知扩增过程会耗尽干细胞池,导致促进细胞凋亡和破坏向骨髓归巢的细胞缺陷。凋亡机制在调节造血系统中的干细胞库中的作用在小鼠造血和胚胎系统中已被推测。我们一直观察到与新鲜分离的对应物相比,用细胞因子培养的脐带血来源的 CD34(+)细胞中的凋亡增加。本研究旨在评估凋亡的药理学抑制是否可以改善扩增的结果。

方法/主要发现:CB CD34(+)细胞在细胞可渗透的 caspase 和 calpain 抑制剂(分别为 zVADfmk 和 zLLYfmk)存在或不存在的情况下用细胞因子进行扩增。观察到凋亡蛋白酶抑制剂在体外扩增过程中增加移植物中 CD34(+)细胞含量的新作用。这进一步反映在 HSPC 的体外功能方面得到改善;更高的集落形成能力和长期培养起始能力。与仅用生长因子扩增的细胞相比,这些细胞在 NOD/SCID 小鼠的骨髓中具有更好的长期植入和主要淋巴骨髓谱系的有效再生。

结论/意义:我们的数据表明,在培养基中使用 zVADfmk 或 zLLYfmk 均可改善 CD34(+)细胞的扩增。该策略保护干细胞池和定向祖细胞,并改善其体外功能和体内植入。这一观察结果可能补充了用于治疗目的的造血细胞操作中使用的现有方案。这些发现可能会对涉及未处理和扩增移植物联合输注的 CB 移植程序产生影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6739/2923186/96d4c0f74893/pone.0012221.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索